Aarti Drugs announces leadership transition effective Oct 1, 2026

Ceo ResignedCfo ResignedKmp ResignedManagement Changes View source PDF Explain this filing

AARTIDRUGS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.6%Reaction day

₹423.00

prior close

₹424.00

announcement price

After-mkt

timing

Nifty Microcap 250market+1.3%-5.0% vs market

Pharmaceuticals peers, median of 163sector+1.0%-4.6% vs sector

On the reaction day the stock moved 5.0 pts less than Nifty Microcap 250 and 4.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.7

10m

-3.0

15m

-2.7

30m

-3.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.6+1.3-5.0+1.0-4.6

Next day

-2.4+1.8-4.1+0.8-3.2

-2.7+3.1-5.7+0.3-3.0

-2.8+3.5-6.3+0.7-3.6

-1.1+3.5-4.6+1.5-2.6

+0.0+3.4-3.4+1.3-1.3

+2.4+3.6-1.3+1.5+0.9

15d

-0.1+4.9-4.9+0.9-1.0

+0.5+4.4-3.9+1.7-1.2

-2.0+2.9-4.9+1.9-3.9

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aarti Drugs announced leadership changes effective Oct 1, 2026. Prakash Patil retires as Chairman, MD and CEO on Sept 30, 2026, ending a tenure since the company inception. Rashesh Gogri, current MD since 2014, is elevated to Chairman in addition to his MD role. Adhish Patil, current CFO since 2014, is appointed as the new MD, subject to shareholder approval at the AGM. Patil senior will continue in an advisory role to support a smooth transition.

Likely market impact

Planned internal succession; long-term strategy unchanged. Watch for AGM approval of the new MD and continuity of growth execution.